300244
vs
Shanghai Composite

Over the past 5 years, has underperformed Shanghai Composite, delivering a return of -49% compared to the Shanghai Composite's 9% growth.

Stocks Performance
300244 vs Shanghai Composite

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Performance Gap
300244 vs Shanghai Composite

Performance Comparison
300244 vs Shanghai Composite

1 Month 3 Months 6 Months 1 Year 5 Years 10 Years 20 Years
Dian Diagnostics Group Co Ltd
-13%
-25%
-4%
-51%
-49%
-44%
139%
Shanghai Composite
Market Index
0%
-4%
12%
13%
9%
0%
170%

Dian Diagnostics Group Co Ltd
Glance View

Market Cap
7.1B CNY
Industry
Health Care

Nestled in the bustling city of Hangzhou, Dian Diagnostics Group Co Ltd has carved out a pivotal role in China's healthcare landscape. Established in 1996, the company's journey began with the humble yet crucial task of providing diagnostic services. Over the years, as the wave of technological innovation swept across the globe, Dian Diagnostics harnessed its potential to expand its service offerings, evolving into a comprehensive medical diagnostics powerhouse. The company operates through its expansive network of diagnostic laboratories, which leverage cutting-edge tools to deliver precise and timely results. This network serves hospitals, clinics, and other healthcare establishments, thus forming a vital link in the healthcare delivery chain. The heart of Dian Diagnostics' business model lies in its ability to integrate advanced technological solutions with healthcare needs, ensuring scalability and efficiency. The company's revenue streams primarily flow from the provision of diagnostic testing services and sales of diagnostic equipment and reagents. Owing to its commitment to innovation, Dian Diagnostics invests heavily in research and development, continuously enhancing its offerings in molecular diagnostics, pathology, and healthcare IT solutions. By catering to the ever-growing demand for reliable and rapid diagnostic services, the company sustains its growth momentum while contributing significantly to the advancement of healthcare quality in China.

Intrinsic Value
28.63 CNY
Undervaluation 60%
Intrinsic Value
Price

See Also

Back to Top